Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial

INTRODUCTION: SLE is a chronic inflammatory systemic autoimmune disease with relapsing–remitting pattern. B-lymphocyte stimulator was involved in the pathogenesis of SLE. The humanised monoclonal antibody belimumab with 10 mg/kg was effective for active patients. However, the efficacy of low-dose be...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Fangfang, Huang, Wenyan, Chen, Jie, Zhao, Liling, Zhang, Danting, Wang, Xiaodong, Wan, Weiguo, Dai, Sheng-Ming, Chen, Sheng, Li, Ting, Ye, Shuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808446/
https://www.ncbi.nlm.nih.gov/pubmed/35105722
http://dx.doi.org/10.1136/lupus-2021-000638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808446/
https://www.ncbi.nlm.nih.gov/pubmed/35105722
http://dx.doi.org/10.1136/lupus-2021-000638

Ejemplares similares